880 Shares in Galapagos NV (GLPG) Purchased by Financial Gravity Companies Inc.
Financial Gravity Companies Inc. acquired a new position in Galapagos NV (NASDAQ:GLPG) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 880 shares of the biotechnology company’s stock, valued at approximately $104,000.
A number of other large investors have also recently added to or reduced their stakes in the business. Northern Trust Corp increased its stake in Galapagos by 2.9% in the 2nd quarter. Northern Trust Corp now owns 18,480 shares of the biotechnology company’s stock worth $1,414,000 after acquiring an additional 524 shares during the last quarter. Cookson Peirce & Co. Inc. increased its stake in Galapagos by 16.2% in the 4th quarter. Cookson Peirce & Co. Inc. now owns 4,060 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 565 shares during the last quarter. Atria Investments LLC increased its stake in Galapagos by 23.0% in the 4th quarter. Atria Investments LLC now owns 3,609 shares of the biotechnology company’s stock worth $338,000 after acquiring an additional 676 shares during the last quarter. Aperio Group LLC increased its stake in Galapagos by 22.2% in the 3rd quarter. Aperio Group LLC now owns 4,159 shares of the biotechnology company’s stock worth $423,000 after acquiring an additional 755 shares during the last quarter. Finally, Advisors Preferred LLC bought a new stake in Galapagos in the 3rd quarter worth approximately $105,000. 19.49% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have issued reports on GLPG. BidaskClub downgraded Galapagos from a “buy” rating to a “hold” rating in a research note on Friday. BTIG Research reaffirmed a “buy” rating and issued a $118.00 price objective on shares of Galapagos in a research note on Thursday, February 8th. ValuEngine raised Galapagos from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research downgraded Galapagos from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 25th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $111.00.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galapagos NV (NASDAQ:GLPG).
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.